Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Deutsche Bank acquired a new 557,937-share stake in Amylyx Pharmaceuticals during the second quarter, valued at approximately $10 million and representing 0.5% of the company. Institutional investors collectively own 95.84% of AMLX.
• AMLX shares opened at $38.66, near their 52-week high of $41.14, after rising above their 50-day and 200-day moving averages. The stock has a $4.31 billion market capitalization, though Amylyx reported a quarterly EPS loss of $0.39, slightly worse than estimates.
• Analyst sentiment is broadly positive, with HC Wainwright raising its price target to $55 and Mizuho to $42; however, investors face potential dilution from Amylyx’s upsized $500 million stock offering, while pivotal LUCIDITY data remains a key upcoming catalyst.

Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company's stock, valued at approximately $10,021,000. Deutsche Bank AG owned 0.50% of Amylyx Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AMLX. Millennium Management LLC raised its position in shares of Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company's stock worth $10,910,000 after acquiring an additional 2,487,617 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company's stock valued at $7,090,000 after acquiring an additional 143,065 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Amylyx Pharmaceuticals by 62.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company's stock valued at $564,000 after purchasing an additional 33,920 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $47,000. Finally, Rhumbline Advisers purchased a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $645,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $38.66 on Monday. Amylyx Pharmaceuticals, Inc. has a 52 week low of $8.46 and a 52 week high of $41.14. The firm has a 50-day simple moving average of $20.37 and a 200-day simple moving average of $16.70. The stock has a market capitalization of $4.31 billion, a P/E ratio of -27.03 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). On average, analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Analyst targets point to further upside. Robert W. Baird raised its price target to $52, while Guggenheim forecast strong potential appreciation. HC Wainwright maintained a Buy rating and a $55 target. Robert W. Baird Raises Amylyx Pharmaceuticals Price Target to $52.00 Guggenheim Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals
• Positive Sentiment: Long-term earnings forecasts improved materially. HC Wainwright increased its FY2029 EPS estimate to $3.22 from $1.66 and its FY2030 estimate to $6.40 from $3.74, reflecting greater confidence in Amylyx’s commercial prospects. HC Wainwright Amylyx earnings estimates
• Positive Sentiment: Trading activity accelerated after the analyst upgrade. Amylyx reached a new 52-week high, and trading volume was substantially above its average, indicating heightened institutional and speculative interest. Amylyx Sees Strong Trading Volume on Analyst Upgrade
• Neutral Sentiment: Pivotal LUCIDITY data remains the key upcoming catalyst. Investors are positioning ahead of the data, which could significantly affect the company’s outlook depending on the results. Amylyx Readies for Pivotal LUCIDITY Data
• Negative Sentiment: Amylyx priced an upsized $500 million stock offering at $35.50 per share. The financing strengthens its cash position for development and commercialization but creates dilution, and the discounted offering price can pressure the stock. Underwriters also received an option to buy an additional 2.11 million shares. Amylyx Announces Pricing of Upsized $500 Million Offering

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMLX. HC Wainwright increased their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Mizuho raised their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. Wall Street Zen cut Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Citigroup upped their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $36.25.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.90% of the company's stock.

Amylyx Pharmaceuticals Company Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source